STOK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -46.35% compared to Stoke Therapeutics's net margin of 9.89%. Stoke Therapeutics's return on equity of -44.32% beat Biogen's return on equity of 9.11%.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 167.36%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 39.86%. Given that Stoke Therapeutics has higher upside potential than Biogen, analysts believe Stoke Therapeutics is more attractive than Biogen.

Stoke Therapeutics has a beta of 1.199, which suggesting that the stock is 19.902% more volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are smaller than Biogen quarterly revenues of $2.4B. Stoke Therapeutics's net income of -$10.5M is lower than Biogen's net income of $240.5M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 12.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.16x versus 1.83x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -46.35% compared to Stoke Therapeutics's net margin of -49.65%. Stoke Therapeutics's return on equity of -44.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 167.36%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.68%. Given that Stoke Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Stoke Therapeutics is more attractive than NovaBay Pharmaceuticals.

Stoke Therapeutics has a beta of 1.199, which suggesting that the stock is 19.902% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Stoke Therapeutics's net income of -$10.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.16x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -46.35% compared to Stoke Therapeutics's net margin of --. Stoke Therapeutics's return on equity of -44.32% beat Theriva Biologics's return on equity of --.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 167.36%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1150%. Given that Theriva Biologics has higher upside potential than Stoke Therapeutics, analysts believe Theriva Biologics is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 1.199, which suggesting that the stock is 19.902% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are larger than Theriva Biologics quarterly revenues of --. Stoke Therapeutics's net income of -$10.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.16x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -46.35% compared to Stoke Therapeutics's net margin of -83.5%. Stoke Therapeutics's return on equity of -44.32% beat Zymeworks's return on equity of -30.32%.

Stoke Therapeutics has a consensus price target of $23.88, signalling upside risk potential of 167.36%. On the other hand Zymeworks has an analysts' consensus of $21.35 which suggests that it could grow by 83.89%. Given that Stoke Therapeutics has higher upside potential than Zymeworks, analysts believe Stoke Therapeutics is more attractive than Zymeworks.

Stoke Therapeutics has a beta of 1.199, which suggesting that the stock is 19.902% more volatile than S&P 500. In comparison Zymeworks has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.318%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $22.6M, which are smaller than Zymeworks quarterly revenues of $27.1M. Stoke Therapeutics's net income of -$10.5M is higher than Zymeworks's net income of -$22.6M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 13.16x versus 9.40x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.